Host Pennie Power examines Ozempic's lifetime financial commitment, breaking down costs from $65,000 for insured patients to potentially $900,000 for the uninsured over 30 years. She explores whether continuous GLP-1 therapy justifies its price tag when weighed against obesity's healthcare costs, using clinical data and cost-effectiveness research to empower listeners with transparent financial analysis.
Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV
This content was created in partnership and with the help of Artificial Intelligence AI
続きを読む
一部表示